{"id":"anti-vegf-injections","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Increased intraocular pressure"},{"rate":"0.1-1%","effect":"Endophthalmitis"},{"rate":"1-5%","effect":"Retinal detachment"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This action helps to reduce the formation of new blood vessels that tumors need to grow and spread. By inhibiting VEGF, anti-VEGF injections can slow or stop the growth of certain cancers.","oneSentence":"Anti-VEGF injections work by binding to and inhibiting vascular endothelial growth factor (VEGF), a protein that promotes angiogenesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:56:46.747Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Wet age-related macular degeneration"},{"name":"Macular edema following retinal vein occlusion"},{"name":"Diabetic macular edema"}]},"trialDetails":[{"nctId":"NCT06890026","phase":"","title":"Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2024-11-15","conditions":"Neovascular Age-Related Macular Degeneration (nAMD), Treatment-naïve","enrollment":742},{"nctId":"NCT05063552","phase":"PHASE2, PHASE3","title":"Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-13","conditions":"Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma","enrollment":430},{"nctId":"NCT06893965","phase":"NA","title":"Acute Intra Ocular Pressure Monitoring After Aflibercept 8mg/0.07mL","status":"RECRUITING","sponsor":"Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","startDate":"2025-07-08","conditions":"Macular Diseases","enrollment":100},{"nctId":"NCT07481500","phase":"NA","title":"Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: A Randomized Trial of Pain, Procedure Time, Patient Satisfaction, and Safety","status":"NOT_YET_RECRUITING","sponsor":"Jakkrit Juhong","startDate":"2026-06","conditions":"Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema, Retinal Vein Occlusion","enrollment":120},{"nctId":"NCT00588770","phase":"PHASE3","title":"Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-08-08","conditions":"Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma","enrollment":403},{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT04514653","phase":"PHASE2","title":"RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-08-25","conditions":"Neovascular Age-Related Macular Degeneration (nAMD)","enrollment":146},{"nctId":"NCT07438119","phase":"PHASE4","title":"Efficacy Comparison of DExamethasone Intravitreal Implant Combined With Aflibercept Versus Aflibercept Monotherapy in Treatment-naïve Inflammatory Diabetic Macular Edema Patients","status":"NOT_YET_RECRUITING","sponsor":"Kun Liu","startDate":"2026-03-15","conditions":"Diabetic Macular Edema (DME)","enrollment":114},{"nctId":"NCT07133438","phase":"PHASE4","title":"Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment","status":"RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2025-08-01","conditions":"Retinal Vein Occlusion (RVO)","enrollment":120},{"nctId":"NCT04503551","phase":"PHASE3","title":"A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-08-10","conditions":"Diabetic Retinopathy","enrollment":174},{"nctId":"NCT03942328","phase":"PHASE1, PHASE2","title":"Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2019-09-19","conditions":"Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8","enrollment":85},{"nctId":"NCT07427719","phase":"","title":"Retinopathy of Prematurity - Visual Function and Retinal Structure","status":"NOT_YET_RECRUITING","sponsor":"Oslo University Hospital","startDate":"2026-04-01","conditions":"Retinopathy of Prematurity (ROP), Prematurity Complications, Cerebral Visual Impairment","enrollment":140},{"nctId":"NCT04704921","phase":"PHASE2, PHASE3","title":"Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD","status":"RECRUITING","sponsor":"AbbVie","startDate":"2020-12-29","conditions":"AMD, nAMD, Wet Age-related Macular Degeneration","enrollment":630},{"nctId":"NCT06709339","phase":"PHASE4","title":"Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Vasculopathy (MONDEGO)","status":"RECRUITING","sponsor":"Association for Innovation and Biomedical Research on Light and Image","startDate":"2025-08-06","conditions":"Polypoidal Choroidal Vasculopathy","enrollment":120},{"nctId":"NCT04743661","phase":"PHASE2","title":"131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pediatric Brain Tumor Consortium","startDate":"2022-04-04","conditions":"Recurrent Medulloblastoma, Recurrent Ependymoma","enrollment":62},{"nctId":"NCT05733611","phase":"PHASE2","title":"RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC","status":"TERMINATED","sponsor":"Replimune Inc.","startDate":"2023-06-29","conditions":"Refractory Metastatic Colorectal Cancer, pMMR, MSS","enrollment":5},{"nctId":"NCT07375901","phase":"NA","title":"the Blood-Aqeous Barrier During Anti-Angiogenic Therapy in Exudative Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"The Filatov Institute of Eye Diseases and Tissue Therapy","startDate":"2021-03-25","conditions":"AMD","enrollment":30},{"nctId":"NCT05984927","phase":"PHASE1, PHASE2","title":"NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Elisigen, Inc.","startDate":"2023-09-08","conditions":"Age-Related Macular Degeneration","enrollment":20},{"nctId":"NCT07338097","phase":"NA","title":"Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema","status":"ENROLLING_BY_INVITATION","sponsor":"CMH Multan Institute of Medical Sciences","startDate":"2025-09-07","conditions":"Diabetic Macular Edema (DME)","enrollment":116},{"nctId":"NCT07329686","phase":"PHASE1, PHASE2","title":"Clinical Study of Intrastromal Anti-VEGF Injection for Corneal Neovascularization.","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-10-01","conditions":"Herpes Simplex Keratitis, Corneal Neovascularization","enrollment":100},{"nctId":"NCT05769153","phase":"PHASE1, PHASE2","title":"Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)","status":"RECRUITING","sponsor":"Alcon Research","startDate":"2023-12-06","conditions":"Neovascular Age-related Macular Degeneration (nAMD)","enrollment":140},{"nctId":"NCT04311606","phase":"PHASE2","title":"Anti-VEGF Therapy for Acute Thyroid Eye Disease","status":"COMPLETED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2020-11-02","conditions":"Thyroid Eye Disease","enrollment":11},{"nctId":"NCT05657301","phase":"PHASE1","title":"Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chengdu Origen Biotechnology Co., Ltd.","startDate":"2023-10-16","conditions":"Age-Related Macular Degeneration","enrollment":25},{"nctId":"NCT00565851","phase":"PHASE3","title":"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2007-12-06","conditions":"Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma","enrollment":1052},{"nctId":"NCT07307053","phase":"PHASE1, PHASE2","title":"Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-01","conditions":"Rare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":600},{"nctId":"NCT07301775","phase":"PHASE4","title":"Comparing Single Versus Multiple Anti-VEGF Injections in Diabetic Patients Undergoing Cataract Surgery","status":"NOT_YET_RECRUITING","sponsor":"Ahmad Zeeshan Jamil","startDate":"2026-01-01","conditions":"Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), Cataract","enrollment":166},{"nctId":"NCT05666804","phase":"PHASE3","title":"Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-02-06","conditions":"Macular Polypoidal Choroidal Vasculopathy (PCV)","enrollment":148},{"nctId":"NCT06537908","phase":"","title":"Anti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCC","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-08-01","conditions":"Hepatocellular Carcinoma","enrollment":50},{"nctId":"NCT03940690","phase":"PHASE3","title":"Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease","status":"TERMINATED","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2019-10-24","conditions":"Retinal Telangiectasis, Coats Disease","enrollment":18},{"nctId":"NCT05802329","phase":"PHASE1","title":"Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)","status":"RECRUITING","sponsor":"Ocugen","startDate":"2024-01-13","conditions":"Center Involved Diabetic Macular Edema, Diabetic Macular Edema","enrollment":24},{"nctId":"NCT00527475","phase":"PHASE2","title":"Ranibizumab and Reduced Fluence PDT for AMD","status":"COMPLETED","sponsor":"Texas Retina Associates","startDate":"2007-05","conditions":"Macular Degeneration","enrollment":60},{"nctId":"NCT04101877","phase":"PHASE2","title":"The Sahlgrenska Anti-VEGF Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2020-09-03","conditions":"Neovascular Age-related Macular Degeneration","enrollment":402},{"nctId":"NCT05142189","phase":"PHASE1","title":"Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2022-06-17","conditions":"Non-Small Cell Lung Cancer","enrollment":280},{"nctId":"NCT06556368","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kodiak Sciences Inc","startDate":"2024-08-23","conditions":"Wet Age-related Macular Degeneration","enrollment":675},{"nctId":"NCT04777201","phase":"PHASE3","title":"A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-04-19","conditions":"Neovascular Age-related Macular Degeneration","enrollment":1036},{"nctId":"NCT04278417","phase":"PHASE3","title":"Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-11-19","conditions":"Proliferative Diabetic Retinopathy","enrollment":689},{"nctId":"NCT06491914","phase":"PHASE3","title":"A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-07-24","conditions":"Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema","enrollment":1118},{"nctId":"NCT04679935","phase":"PHASE4","title":"Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-07-13","conditions":"Age-related Macular Degeneration","enrollment":52},{"nctId":"NCT05407636","phase":"PHASE3","title":"Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD","status":"RECRUITING","sponsor":"AbbVie","startDate":"2022-01-13","conditions":"AMD, nAMD, Wet Age-related Macular Degeneration","enrollment":660},{"nctId":"NCT05542381","phase":"NA","title":"The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain","status":"COMPLETED","sponsor":"Virginia Polytechnic Institute and State University","startDate":"2022-12-22","conditions":"Age-Related Macular Degeneration","enrollment":64},{"nctId":"NCT04567550","phase":"PHASE2","title":"RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-11-20","conditions":"Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME)","enrollment":139},{"nctId":"NCT05456828","phase":"PHASE1","title":"A Study of ASKG712 in Patients With Neovascular Age-Related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"AskGene Pharma, Inc.","startDate":"2023-02-10","conditions":"Neovascular Age-related Macular Degeneration","enrollment":56},{"nctId":"NCT05940428","phase":"PHASE1","title":"A Study of ASKG712 in Patients With Diabetic Macular Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"AskGene Pharma, Inc.","startDate":"2023-10-23","conditions":"Diabetic Macular Edema","enrollment":26},{"nctId":"NCT07144865","phase":"NA","title":"Biological Changes in Fibrovascular Membranes of Patients With Proliferative Diabetic Retinopathy Following Faricimab Injection","status":"COMPLETED","sponsor":"Bojie Hu","startDate":"2024-12-01","conditions":"Proliferative Diabetic Retinopathy","enrollment":8},{"nctId":"NCT00334815","phase":"PHASE2","title":"Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2006-06-15","conditions":"Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Large Cell Carcinoma","enrollment":29},{"nctId":"NCT05536973","phase":"PHASE2","title":"Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]","status":"ACTIVE_NOT_RECRUITING","sponsor":"Adverum Biotechnologies, Inc.","startDate":"2022-08-23","conditions":"Neovascular Age-related Macular Degeneration","enrollment":69},{"nctId":"NCT07106268","phase":"","title":"Aqueous Humor Proteome in Retinal Vein Occlusion With Macular Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tianjin Medical University Eye Hospital","startDate":"2023-03-01","conditions":"Retinal Vein Occlusion","enrollment":100},{"nctId":"NCT06011798","phase":"PHASE2","title":"Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)","status":"COMPLETED","sponsor":"Unity Biotechnology, Inc.","startDate":"2023-08-23","conditions":"Diabetic Macular Edema, Retinal Disease, Macular Edema","enrollment":52},{"nctId":"NCT06845163","phase":"PHASE2","title":"Randomized Clinical Trial to Evaluate the Effect of Dapagliflozin in Patients With Diabetic Macular Edema","status":"RECRUITING","sponsor":"Alexandria University","startDate":"2025-02-08","conditions":"Diabetic Macular Edema, Center-involved Diabetic Macular Edema","enrollment":56},{"nctId":"NCT07014280","phase":"PHASE4","title":"Bevacizumab Versus Triamcinolone Acetonide for the Treatment of Keloids.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kasr El Aini Hospital","startDate":"2023-09-01","conditions":"Keloids","enrollment":28},{"nctId":"NCT04420923","phase":"NA","title":"Optimizing the Treatment Strategy for Age-related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Olavs Hospital","startDate":"2020-05-20","conditions":"Wet Macular Degeneration","enrollment":250},{"nctId":"NCT07009574","phase":"","title":"The Treatment Burden of Myopic Choroidal Neovascularization","status":"NOT_YET_RECRUITING","sponsor":"Policlinico Gaspare Rodolico - San Marco Catania","startDate":"2025-06-01","conditions":"Myopic Choroidal Neovascularisation, Anti-VEGF Treatment, Burden","enrollment":100},{"nctId":"NCT06498050","phase":"PHASE4","title":"Brolucizumab Efficacy and Safety Single-Arm Descriptive Trial in Patients With Persistent Diabetic Macular Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2024-07-10","conditions":"Diabetic Macular Edema","enrollment":52},{"nctId":"NCT07002372","phase":"NA","title":"Effect of Video Viewing on Intravitreal Injection Experience","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-05-05","conditions":"Age Related Macular Degeneration, Diabetic Retinopathy, Choroidal Neovascularization","enrollment":182},{"nctId":"NCT05941325","phase":"PHASE2","title":"A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"Shanghai 6th People's Hospital","startDate":"2023-04-01","conditions":"Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma","enrollment":20},{"nctId":"NCT05604989","phase":"PHASE3","title":"Associations Between the Oral and Intestinal Microbiome and Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2023-01-01","conditions":"Neovascular Age-related Macular Degeneration","enrollment":45},{"nctId":"NCT04774926","phase":"PHASE4","title":"Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-10-15","conditions":"Neovascular Age-related Macular Degeneration","enrollment":122},{"nctId":"NCT06951087","phase":"PHASE3","title":"Intravitreal and Intracameral DEX in NPDR","status":"ENROLLING_BY_INVITATION","sponsor":"Affiliated Hospital of Nantong University","startDate":"2022-01-31","conditions":"Non-Proliferative Diabetic Retinopathy","enrollment":80},{"nctId":"NCT06944470","phase":"PHASE2","title":"JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2025-04-20","conditions":"NSCLC","enrollment":76},{"nctId":"NCT06929507","phase":"NA","title":"Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients","status":"RECRUITING","sponsor":"University Hospital, Alexandroupolis","startDate":"2025-03-10","conditions":"Renal Function Disorder, Diabetic Macular Edema (DME), Neovascular Age Related Macular Degeneration","enrollment":60},{"nctId":"NCT06902207","phase":"","title":"Real-world Incidence of Intraocular Inflammation Following Intravitreal Faricimab Therapy","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2024-11-10","conditions":"Intraocular Inflammation","enrollment":6053},{"nctId":"NCT06270836","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kodiak Sciences Inc","startDate":"2024-05-01","conditions":"Diabetic Retinopathy","enrollment":255},{"nctId":"NCT03585556","phase":"PHASE1","title":"AAVCAGsCD59 for the Treatment of Wet AMD","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-09-13","conditions":"Wet Age-related Macular Degeneration","enrollment":25},{"nctId":"NCT06511700","phase":"","title":"Implementation of the Intravitreal Injection Administered by Nurses","status":"ENROLLING_BY_INVITATION","sponsor":"Corporacion Parc Tauli","startDate":"2025-01-15","conditions":"Macular Edema, Macular Degeneration, Diabetic Macular Edema","enrollment":200},{"nctId":"NCT05003245","phase":"PHASE3","title":"Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2021-11-01","conditions":"Age Related Macular Degeneration","enrollment":407},{"nctId":"NCT03172299","phase":"PHASE3","title":"Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated with Proton Therapy for a Large Choroidal Melanoma","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2017-06-08","conditions":"Ocular Melanoma","enrollment":57},{"nctId":"NCT02397954","phase":"PHASE2","title":"A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)","status":"COMPLETED","sponsor":"Ophthotech Corporation","startDate":"2015-03-12","conditions":"Idiopathic Polypoidal Choroidal Vasculopathy","enrollment":4},{"nctId":"NCT06878573","phase":"","title":"Change in Ocular Perfusion After Intravitreal Anti-VEGF in Patients with Age-related Maculopathy or Diabetic Macula Edema","status":"COMPLETED","sponsor":"Augenabteilung Allgemeines Krankenhaus Linz","startDate":"2023-11-22","conditions":"Age Related Macular Degeneration, Diabetic Macular Edema","enrollment":36},{"nctId":"NCT05571267","phase":"PHASE2","title":"Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD","status":"TERMINATED","sponsor":"IVERIC bio, Inc.","startDate":"2016-10-20","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":1},{"nctId":"NCT05698329","phase":"PHASE1","title":"Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AiViva BioPharma, Inc.","startDate":"2023-03-02","conditions":"Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Macular Edema","enrollment":19},{"nctId":"NCT00324805","phase":"PHASE3","title":"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-07-19","conditions":"Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7","enrollment":1501},{"nctId":"NCT05976139","phase":"NA","title":"Micropulsed Laser in Patients With Macular Oedema in Retinal Dystrophies","status":"RECRUITING","sponsor":"Fondazione G.B. Bietti, IRCCS","startDate":"2023-09-06","conditions":"Macular Edema, Inherited Retinal Dystrophy, Laser Retinopathy","enrollment":10},{"nctId":"NCT06846073","phase":"NA","title":"Early Combined Use of Dexamethasone Intravitreal Implant and Anti-VEGF in the Treatment of DME.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-07-30","conditions":"Diabetic Macular Edema (DME)","enrollment":70},{"nctId":"NCT06841250","phase":"","title":"Early Changes in OCT Biomarkers After the First Intravitreal Anti-VEGF Injection in Treatment-naïve DME","status":"ENROLLING_BY_INVITATION","sponsor":"Sohag University","startDate":"2025-01-16","conditions":"Early OCT Biomarker Changes in Response to Anti-VEGF","enrollment":50},{"nctId":"NCT04707625","phase":"PHASE4","title":"Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2021-10-06","conditions":"Retinal Vein Occlusion","enrollment":17},{"nctId":"NCT06838546","phase":"PHASE2","title":"A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tasly Biopharmaceuticals Co., Ltd.","startDate":"2025-02-24","conditions":"Advanced Colorectal Cancer","enrollment":80},{"nctId":"NCT05640895","phase":"","title":"Intravitreal Injection Site and Perceived Pain","status":"COMPLETED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2022-11-14","conditions":"Pain","enrollment":53},{"nctId":"NCT06610747","phase":"NA","title":"Home- vs Hospital-based Care of Anti-VEGF Treatment for Diabetic Macular Edema: Non-inferiority RCT","status":"RECRUITING","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2024-10-28","conditions":"Diabetic Macular Edema","enrollment":308},{"nctId":"NCT05003258","phase":"NA","title":"Functional and Anatomical Outcomes of Dexamethasone Intra-vitreal Implant in Patients with Resistant Macular Edema Secondary to Retinal Vein Occlusion After Intravitreal Anti-VEGF Injection","status":"COMPLETED","sponsor":"Assiut University","startDate":"2021-10-07","conditions":"Macular Edema, Retinal Vein Occlusion","enrollment":25},{"nctId":"NCT06771271","phase":"PHASE1","title":"A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-07-22","conditions":"Diabetic Macular Edema, Uveitic Macular Edema","enrollment":85},{"nctId":"NCT05610319","phase":"PHASE4","title":"Treat & Extend Versus Fixed Dosing with Faricimab for Management of Diabetic Macular Edema: a Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"McMaster University","startDate":"2023-05-01","conditions":"Diabetic Macular Edema","enrollment":446},{"nctId":"NCT04740671","phase":"PHASE3","title":"A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2021-07-01","conditions":"Age Related Macular Degeneration","enrollment":410},{"nctId":"NCT06723964","phase":"PHASE1","title":"A Study of AP505 Injection in Patients With Advanced Malignant Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"AP Biosciences Inc.","startDate":"2023-03-30","conditions":"Advanced Solid Tumors","enrollment":35},{"nctId":"NCT06724263","phase":"PHASE2","title":"A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tasly Biopharmaceuticals Co., Ltd.","startDate":"2024-12","conditions":"Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Cervical Cancers","enrollment":120},{"nctId":"NCT06710951","phase":"NA","title":"Effect of Povidone-iodine 5% Vs 1% on the Ocular Surface in Intravitreal Injections of Anti-VEGF","status":"COMPLETED","sponsor":"José Gerardo García Aguirre","startDate":"2021-11-15","conditions":"Dry Eye","enrollment":88},{"nctId":"NCT05672121","phase":"PHASE1, PHASE2","title":"Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)","status":"RECRUITING","sponsor":"Chengdu Origen Biotechnology Co., Ltd.","startDate":"2023-02-06","conditions":"Age-Related Macular Degeneration","enrollment":42},{"nctId":"NCT05152862","phase":"","title":"Improve Screening Criteria for Retinopathy of Prematurity in Two French Center","status":"COMPLETED","sponsor":"Centre Hospitalier Sud Francilien","startDate":"2022-03-21","conditions":"Retinopathy of Prematurity","enrollment":886},{"nctId":"NCT06699914","phase":"","title":"A Study to Evaluate Real-world Brolucizumab Effectiveness and Safety in Japanese Patients With Neovascular Age-related Macular Degeneration (nAMD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-09-06","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":438},{"nctId":"NCT04264819","phase":"PHASE3","title":"Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-12-14","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":295},{"nctId":"NCT02387957","phase":"PHASE2","title":"A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)","status":"TERMINATED","sponsor":"Ophthotech Corporation","startDate":"2016-04-26","conditions":"Age-Related Macular Degeneration","enrollment":63},{"nctId":"NCT05473715","phase":"PHASE4","title":"A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment","status":"TERMINATED","sponsor":"Bayer","startDate":"2023-04-25","conditions":"Neovascular (Wet) Age-related Macular Degeneration","enrollment":3},{"nctId":"NCT03396861","phase":"PHASE1","title":"Treatment of Macular Edema After Cataract Surgery with Subconjunctival Aflibercept","status":"TERMINATED","sponsor":"Tufts Medical Center","startDate":"2019-02-22","conditions":"Irvine-Gass Syndrome","enrollment":1},{"nctId":"NCT04239027","phase":"PHASE3","title":"A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-01-26","conditions":"Neovascular Age Related Macular Degeneration","enrollment":210},{"nctId":"NCT04597632","phase":"PHASE3","title":"An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-12-16","conditions":"Neovascular Age-related Macular Degeneration","enrollment":248},{"nctId":"NCT06577376","phase":"PHASE1, PHASE2","title":"A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","startDate":"2024-08-26","conditions":"Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma, Expressing Human Epidermal Growth Factor Receptor-2 (HER-2), Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past","enrollment":252},{"nctId":"NCT05066230","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)","status":"TERMINATED","sponsor":"Kodiak Sciences Inc","startDate":"2021-09-07","conditions":"Non-proliferative Diabetic Retinopathy","enrollment":253},{"nctId":"NCT06572553","phase":"PHASE2, PHASE3","title":"Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-03-01","conditions":"Age-Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion","enrollment":30},{"nctId":"NCT04603937","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)","status":"TERMINATED","sponsor":"Kodiak Sciences Inc","startDate":"2020-09-30","conditions":"Diabetic Macular Edema","enrollment":459},{"nctId":"NCT04611152","phase":"PHASE3","title":"A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)","status":"TERMINATED","sponsor":"Kodiak Sciences Inc","startDate":"2020-09-30","conditions":"Diabetic Macular Edema","enrollment":460},{"nctId":"NCT06550752","phase":"PHASE1, PHASE2","title":"Erectile Dysfunction Treatment Using Stem Cells","status":"NOT_YET_RECRUITING","sponsor":"COR clinic of Regenerative Medicine","startDate":"2024-08-10","conditions":"Erectile Dysfunction","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Anti-VEGF injections","genericName":"Anti-VEGF injections","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anti-VEGF injections work by binding to and inhibiting vascular endothelial growth factor (VEGF), a protein that promotes angiogenesis. Used for Wet age-related macular degeneration, Macular edema following retinal vein occlusion, Diabetic macular edema.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}